Table 2 FUMA top 10 gene ontology (GO) and canonical pathway enrichment categories of ~1,183 genes that map to differentially methylated probes in primary EWAS (left) and comparable gene list from supplementary EWAS that included all CpGs regardless of blood-brain correlation (right).
RANK | Gene set | N overlap (N genes) | p | adjP | Gene Set | N overlap (N genes) | p | adjP |
|---|---|---|---|---|---|---|---|---|
Primary EWAS (blood-brain correlated CpGs)a | Supplementary EWAS (all CpGs)a | |||||||
GO biological processes | ||||||||
1 | Biological adhesionb | 128 (1404) | 7.88E−26 | 5.79E−22 | Neurogenesis | 152 (1594) | 1.70E−32 | 1.25E−28 |
2 | Homophilic cell adhesion via plasma membrane adhesion molecules | 41 (165) | 1.37E−24 | 5.04E−21 | Neuron differentiation | 128 (1343) | 2.47E−27 | 9.08E−24 |
3 | Cell–cell signalling | 137 (1638) | 4.77E−24 | 1.17E−20 | Positive regulation of biosynthetic process | 160 (1966) | 1.78E−26 | 4.37E−23 |
4 | Cell–cell adhesion via plasma membrane adhesion molecules | 50 (271) | 2.20E−23 | 4.05E−20 | Positive regulation of gene expression | 154 (1955) | 4.99E−24 | 9.18E−21 |
5 | Cell–cell adhesion | 87 (819) | 4.78E−22 | 7.03E−19 | Central nervous system development | 99 (972) | 2.25E−23 | 3.31E−20 |
6 | Synaptic signalling | 73 (712) | 8.10E−18 | 9.92E−15 | Sensory organ development | 70 (535) | 7.72E−23 | 9.46E−20 |
7 | Ion transport | 121 (1663) | 1.53E−16 | 1.61E−13 | Positive regulation of RNA biosynthetic process | 132 (1592) | 1.43E−22 | 1.51E−19 |
8 | Positive regulation of molecular function | 121 (1740) | 4.19E−15 | 3.85E−12 | Animal organ morphogenesis | 100 (1030) | 4.63E−22 | 4.25E−19 |
9 | Synapse assembly | 31 (175) | 1.63E−14 | 1.33E−11 | Biological adhesionb | 120 (1404) | 1.24E−21 | 1.01E−18 |
10 | Synapse organization | 47 (404) | 6.41E−14 | 4.71E−11 | Growth | 96 (979) | 1.62E−21 | 1.19E−18 |
GO cellular components | ||||||||
1 | Intrinsic component of plasma membrane | 145 (1697) | 2.26E−26 | 2.26E−23 | Neuron partb | 150 (1709) | 3.48E−28 | 3.48E−25 |
2 | Synapseb | 107 (1169) | 8.30E−22 | 4.16E−19 | Cell junctionb | 113 (1275) | 1.23E−21 | 6.17E−19 |
3 | Neuron partb | 130 (1709) | 2.66E−19 | 8.88E−17 | Plasma membrane regionb | 104 (1185) | 1.16E−19 | 3.14E−17 |
4 | Cell junctionb | 106 (1275) | 1.53E−18 | 3.83E−16 | Synapseb | 103 (1169) | 1.33E−19 | 3.14E−17 |
5 | Synapse partb | 85 (932) | 2.05E−17 | 4.11E−15 | Neuron projectionb | 110 (1301) | 1.57E−19 | 3.14E−17 |
6 | Neuron projectionb | 102 (1301) | 3.68E−16 | 6.15E−14 | Cell projection partb | 115 (1438) | 1.56E−18 | 2.60E−16 |
7 | Plasma membrane regionb | 94 (1185) | 2.81E−15 | 4.01E−13 | Intrinsic component of plasma membrane | 124 (1697) | 7.63E−17 | 1.09E−14 |
8 | Postsynapse | 61 (610) | 1.35E−14 | 1.68E−12 | Somatodendritic compartment | 77 (818) | 1.82E−16 | 2.27E−14 |
9 | Cell projection partb | 103 (1438) | 8.84E−14 | 9.84E−12 | Cytoskeletal part | 119 (1639) | 5.43E−16 | 6.04E−14 |
10 | Whole membrane | 111 (1647) | 4.82E−13 | 4.82E−11 | Synapse partb | 81 (932) | 2.69E−15 | 2.70E−13 |
GO molecular function | ||||||||
1 | Calcium ion binding | 79 (693) | 5.41E−22 | 8.91E−19 | Sequence-specific DNA bindingb | 106 (1114) | 1.15E−22 | 1.90E−19 |
2 | Ribonucleotide bindingb | 123 (1885) | 2.23E−13 | 1.83E−10 | Regulatory region nucleic acid bindingb | 91 (934) | 2.96E−20 | 2.43E−17 |
3 | Drug bindingb | 112 (1718) | 3.09E−12 | 1.70E−09 | DNA binding transcription factor activity | 128 (1691) | 1.37E−18 | 7.49E−16 |
4 | Adenyl nucleotide binding | 101 (1536) | 2.41E−11 | 9.91E-09 | Sequence-specific double-stranded DNA bindingb | 83 (860) | 2.59E−18 | 1.06E−15 |
5 | Sequence-specific DNA bindingb | 78 (1114) | 3.01E−10 | 9.28E−08 | Double-stranded DNA bindingb | 88 (952) | 3.60E−18 | 1.19E−15 |
6 | Regulatory region nucleic acid bindingb | 69 (934) | 3.54E−10 | 9.28E−08 | Drug bindingb | 125 (1718) | 7.84E−17 | 2.01E−14 |
7 | Transmembrane transporter activity | 74 (1038) | 3.95E−10 | 9.28E−08 | Ribonucleotide bindingb | 133 (1885) | 8.55E−17 | 2.01E−14 |
8 | Double-stranded DNA bindingb | 69 (952) | 7.90E−10 | 1.62E−07 | Adenyl nucleotide binding | 114 (1536) | 5.06E−16 | 1.04E−13 |
9 | Sequence-specific double-stranded DNA bindingb | 64 (860) | 1.17E−09 | 2.13E−07 | Cytoskeletal protein binding | 83 (948) | 7.90E−16 | 1.44E−13 |
10 | Ion transmembrane transporter activity | 64 (870) | 1.84E−09 | 2.76E−07 | Identical protein binding | 118 (1706) | 2.24E−14 | 3.69E−12 |
Canonical pathways (Reactome) | ||||||||
1 | Neuronal systemb | 52 (410) | 7.87E−17 | 1.73E−13 | Neuronal systemb | 44 (410) | 8.06E−12 | 1.77E−08 |
2 | Protein proteinb interactions at synapses | 21 (87) | 5.20E−13 | 5.71E−10 | Extracellular matrix organization | 35 (299) | 1.03E−10 | 1.13E−07 |
3 | Transmission across chemical synapsesb | 33 (269) | 8.46E−11 | 6.20E−08 | Transport of small molecules | 55 (728) | 1.31E−08 | 9.61E−06 |
4 | Neurotransmitter receptors and postsynaptic signal transmissionb | 28 (204) | 1.66E−10 | 9.10E−08 | Axon guidance | 45 (551) | 2.90E−08 | 1.38E−05 |
5 | Neurexins and neuroligins | 15 (56) | 2.21E−10 | 9.71E−08 | Developmental biology | 72 (1100) | 3.14E−08 | 1.38E−05 |
6 | Activation of NMDA receptors and postsynaptic events | 17 (92) | 6.95E−09 | 2.55E−06 | NABA matrisomeb | 68 (1024) | 4.42E−08 | 1.62E−05 |
7 | Disease | 68 (1072) | 1.88E−07 | 5.92E−05 | Signalling by receptor tyrosine kinases | 39 (468) | 1.43E−07 | 4.17E−05 |
8 | NABA core matrisomeb | 26 (274) | 1.39E−06 | 0.000382 | Protein protein interactions at synapsesb | 15 (87) | 1.52E−07 | 4.17E−05 |
9 | CREB1 phosphorylation through NMDAR-mediated activation of RAS signalling | 8 (28) | 2.21E−06 | 0.00054 | Neurotransmitter receptors and postsynaptic signal transmissionb | 23 (204) | 3.14E−07 | 7.29E−05 |
10 | GPCR ligand binding | 35 (453) | 2.94E−06 | 0.000598 | Transmission across chemical synapsesb | 27 (269) | 3.32E−07 | 7.29E−05 |